查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
BCG 疫苗全球市場-2022-2029
市場調查報告書
商品編碼
1140729

BCG 疫苗全球市場-2022-2029

Global BCG Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

新興和欠發達國家結核病患病率上升推動市場增長

世界許多地區，尤其是印度、中國和非洲等發展中國家和欠發達國家的結核病患病率不斷上升，這將刺激對唯一一種針對這種疾病的疫苗——卡介苗疫苗的需求。我猜。根據《2020 年世界結核病報告》，大多數結核病病例發生在東南亞 (43%)、非洲 (25%)、西太平洋 (18%)、東地中海 (8.3%)、美洲 (3.0%) 和歐洲（3.0%）。2.3%）的份額較小。 30個高負擔國家佔全球估計發病率的86%，包括印度（26%）、中國（8.5%）、印度尼西亞（8.4%）、菲律賓（6.0%）和巴基斯坦（5.8%）、尼日利亞（4.6%）、孟加拉（3.6%）、南非（3.3%）等八個國家佔世界總量的三分之二。新興國家如此高的流行率在預測期內推動了卡介苗疫苗市場。

但是，卡介苗疫苗的一些副作用會對市場的增長產生負面影響。 BCG 疫苗對個人的副作用是預計在預測期內抑制全球市場增長的關鍵因素。此外，新興國家卡介苗供應不足也是預計近期阻礙整體市場增長的因素之一。據美國泌尿外科協會稱，美國唯一的 BCG 製造商默克公司已告知 AUA，由於全球範圍內對 BCG 的使用和需求不斷增長，該產品在全球範圍內出現短缺。我正在通知您。作為回應，默克公司提高了卡介苗的產量，預計到 2020 年將持續出現劑量短缺。

地理滲透

在預測期內，亞太地區佔據了絕大多數份額。

該研究按地區分析了全球市場的卡介苗疫苗市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

在預測期內，亞太地區在全球卡介苗疫苗市場中佔有很大的市場份額。在亞洲，預計印度在預測期內將出現顯著增長。在印度，到 2021 年，所有年齡段的各種形式結核病的人均患病率為 312 人，其中德裡所有形式的結核病患病率最高，為人均 747 人，古吉拉特邦最低，為人均 137 人。

此外，預計在預測期內，中東和非洲的價值將出現顯著增長。由於該地區結核病患者人數的增加以及政府抗擊結核病的力度加大，預計亞太地區的卡介苗疫苗市場將在預測期內快速增長。

競爭格局

由於疫苗生產的大規模發展，BCG 疫苗市場是一個競爭激烈的市場。為全球市場增長做出貢獻的主要 BCG 疫苗製造商包括默克實驗室、InterVax Ltd.、GreenSignal Bio Pharma Limited (GSBPL) 和 Statens Serum Institute。領先公司正在為 BCG 疫苗市場的全球增長採取新產品發布和擴張戰略。 2021 年 1 月，默克在美國開設了一家新工廠，以擴大其 Tice BCG 製造能力。 2020 年 7 月，Serum Labs 對 BCG 疫苗進行了 3 期臨床試驗。印度血清研究所正在對其 BCG 候選疫苗 VPM1002 進行 3 期臨床試驗，以評估其在老年高危人群中減少 COVID-19 感染和嚴重後果的能力。 2020 年 9 月，印度血清研究所與比爾和梅琳達·蓋茨基金會合作，為中低收入國家提供了 1 億劑 COVID-19 疫苗。這種合作為印度血清研究所提供了增加製造能力的前期資金。這種合作將大大有助於加快 COVID-19 疫苗的開發並確保快速和全球獲得。

COVID-19 對全球 BCG 疫苗市場的負面影響。

COVID-19 的爆發對全球 BCG 疫苗市場的增長產生了負面影響。在大流行期間，供應鏈中斷對市場增長產生了重大影響。對 COVID-19 疫苗開發的日益關注導致 BCG 疫苗的除垢。因此，COVID-19 大流行正在抑制 2020 年 BCG 疫苗市場的市值。

全球 BCG 疫苗市場報告提供大約 55 個市場數據表、49 個圖表和 170 頁結構

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品劃分的市場細分
  • 按人口統計的市場細分
  • 按應用劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 發展中國家和欠發達國家的結核病患病率不斷上升
      • 全球出生率不斷上升
    • 抑制因素
      • 卡介苗疫苗的副作用
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST 分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品分類

  • 免疫系統 BCG
  • 治療性卡介苗

第 8 章按人口統計

  • 兒科（0-18 歲）
  • 成人（19-35 歲）

第 9 章按應用程序

  • 醫院
  • 醫務室

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • Merck & Co.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Sanofi Pasteur
  • Japan BCG Laboratory
  • China National Biotech Group
  • Serum Institute of India Pvt. Ltd
  • InterVax Ltd
  • GREENSIGNAL BIO PHARMA LIMITED（GSBPL）
  • STATENS SERUM INSTITUTE
  • Other companies（List Not Exhaustive）

第 13 章重要注意事項

第 14 章 DataM

簡介目錄
Product Code: DMHCIT3107

Market Overview

BCG Vaccine Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a highCAGR during the forecast period (2022-2029).

The only vaccine available to combat Tuberculosis is the Bacillus Calmette-Gurin (BCG) vaccine (TB). One dose is recommended for healthy babies near the time of birth in countries with a high incidence of Tuberculosis. However, only infants at high risk are usually immunized in areas where Tuberculosis is rare, while confirmed cases of Tuberculosis are personally screened and administered. It is also possible to immunize individuals who are not afflicted with Tuberculosis and who have not been recently immunized yet are also susceptible to drug-resistant Tuberculosis. The major factors propelling the growth of the BCG vaccine market are Increases in tuberculosis prevalence, especially in developing and underdeveloped countries, as well as technical developments in the field of vaccine research. Also, the rising birth rates across the globe, especially in China and India, contribute to the market's significant growth. Also, the rise in government policies and a global emphasis on immunization programs further drive demand growth. It is expected that untapped business opportunities in emerging regions can have multiple market growth prospects.

Market Dynamics: Increasing prevalence of Tuberculosis in developing and under-developed countries drives market growth

The increasing prevalence of Tuberculosis across the globe, especially in developing and under-developed countries such as India, China, and Africa, will stir the demand for the BCG vaccine as it is the only vaccine available for the disease. As per the global TB report 2020, most TB cases were in the WHO regions of South-East Asia (43%), Africa (25%) and the Western Pacific (18%), with smaller shares in the Eastern Mediterranean (8.3%), the Americas (3.0%) and Europe (2.3%). The 30 high TB burden countries accounted for 86% of all estimated incident cases worldwide, and eight of these countries accounted for two-thirds of the global total: India (26%), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%) and South Africa (3.3%). This high prevalence in emerging countries drives the market for BCG vaccines during the forecast period.

However, some side effects of the BCG vaccine adversely affect market growth. The side effects of the BCG vaccine among individuals are a key factor expected to curtail the global market's growth over the forecast period. Moreover, the shortage of supply in BCG vaccines in emerging countries is another factor expected to hinder the total market's growth in the near future. According to the American Urology Association, Merk and Company is the only producer of BCG in the United States informed the AUA that they were experiencing a global shortage of BCG due to the growing use and need for this product around the world. In comparison, Merck has raised the production of BCG as they expected the shortage of doses to carry through 2020.

Market Segmentation: The Immune BCG segment will project the fastest growth in the market throughout the forecast period

Based on the product, the BCG vaccine market has been classified into Immune BCG and Therapy BCG.

Immune BCG dominated the global market in 2021. Also, the Immune BCG is expected to present considerable growth shortly. BCG Vaccine is administered to newborns in the risk zone areas with a single dose of Immune BCG to prevent TB development. Therefore, the increasing usage of Immune BCG in the prevention of the development of TB is expected to propel segmental growth shortly.

BCG Vaccine is segmented on the basis of demographics, which includes Pediatrics (0-18 Years), Adults (19-35 Years).

The pediatrics (0-18 Years) segment held a significant market share in the forecast period. Pediatrics (0-18 Years) held the dominant position in the global market during the forecast period. In countries where the BCG vaccine is part of the national childhood immunization policy, BCG is normally offered to all children up to one year of age. In addition, older children (over 1 year of age) who have an elevated chance of contracting Tuberculosis should also be given this vaccine. It is rarely administered above 16 years of age and is never administered above 35 years of age since vaccines are only successful when administered at an early stage of life. It supports segment growth during the forecast period.

BCG Vaccine is segmented on the basis of Application, which includes Hospitals, Clinics, Others.

The hospital's segment held a significant market share in the forecast period. The administration of BCG vaccines done after the birth of a baby in the hospitals supports the segment growth during the forecast period. Moreover, the Clinics are expected to project a considerable CAGR during the forecast period. Older children (more than 1 year of age) who have an elevated risk of contracting Tuberculosis may also receive this vaccine administered at Clinics.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period.

Based on geography, the study analyzes the BCG vaccine market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Asia Pacific region held a significant market share in the global BCG vaccine market in the forecast period. India is expected to represent considerable growth in Asia during the forecast period. In India, the prevalence of all forms of TB for all ages in India was 312 per lakh population in 2021, the highest prevalence for all forms of TB was 747 per lakh in Delhi, and the lowest was 137 per lakh population in Gujarat.

Moreover, the Middle East and Africa are expected to represent significant growth in value during the forecast period. BCG Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of tuberculosis cases in the region coupled with increasing government initiatives to combat the disease.

Competitive Landscape:

The BCG vaccine market is highly competitive, owing to the presence of major developments in vaccine production. The key BCG Vaccine players which are contributing to the growth of the global market include Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotech Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institute among others. The major players are adopting new product launches and expansion strategies for global growth in the BCG Vaccine market. In January 2021, Merk constructed a new facility in the United States to expand manufacturing capacity for Tice BCG. In July 2020, the Serum institute conducted a phase 3 clinical trial for the BCG vaccine. The Serum Institute of India is conducting a phase III clinical trial of BCG vaccine candidate VPM1002 to evaluate its ability to reduce infection and severe disease outcomes of COVID-19 among high-risk persons of advanced age. In September 2020, the Serum Institute of India and Bill & Melinda Gates Foundation collaborated to make 100 million doses of COVID-19 vaccine available to low and middle-income countries. This collaboration provided upfront capital to Serum Institute of India to increase its manufacturing capacity. This collaboration majorly helps to boost the development of COVID-19 vaccines and ensure rapid, global access to them.

COVID-19 Impact: Negative impact on the global BCG vaccine market.

The outbreak of COVID-19 has negatively impacted the growth of the BCG vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development has led to de-escalation in BCG vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the BCG Vaccine market in 2020.

The global BCG vaccine market report would provide an access to approximately 55 market data tables, 49 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Demographics
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Tuberculosis in Developing and under-developed countries
      • 4.1.1.2. Increasing birth rates across the globe
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of BCG vaccine
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Immune BCG*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Therapy BCG

8. By Demographics

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics Segment
  • 8.3. Market Attractiveness Index, By Demographics Segment
    • 8.3.1. Pediatrics (0-18 Years)*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Adults (19-35 Years)

9. By Application

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 9.3. Market Attractiveness Index, By Application Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi Pasteur
  • 12.3. Japan BCG Laboratory
  • 12.4. China National Biotech Group
  • 12.5. Serum Institute of India Pvt. Ltd
  • 12.6. InterVax Ltd
  • 12.7. GREENSIGNAL BIO PHARMA LIMITED (GSBPL)
  • 12.8. STATENS SERUM INSTITUTE
  • 12.9. Other companies (List Not Exhaustive)

13. Premium Insights

14. DataM Intelligence Analysis

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us